Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Can parallel CAR-T targeting finally solve relapse in multiple myeloma Can dual-targeting CAR-T solve relapse in multiple myeloma? Explore how Tempest Therapeutics, Inc. is positioning TPST-2003 for next-gen impact. bySoujanya RaviMay 2, 2026